{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:03:34Z","timestamp":1778904214504,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["MAT2017-83858-C2-1"],"award-info":[{"award-number":["MAT2017-83858-C2-1"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["MAT2017-83858-C2-2"],"award-info":[{"award-number":["MAT2017-83858-C2-2"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-113281RB-C21"],"award-info":[{"award-number":["PID2020-113281RB-C21"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-113281RB-C22"],"award-info":[{"award-number":["PID2020-113281RB-C22"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PRE2018-083951"],"award-info":[{"award-number":["PRE2018-083951"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","award":["UCM-Santander fellowship (CT17\/17-CT17-18)."],"award-info":[{"award-number":["UCM-Santander fellowship (CT17\/17-CT17-18)."]}],"id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This work focused on the co-encapsulation and simultaneous co-delivery of three different neuroprotective drugs in PLGA (poly(lactic-co-glycolic acid) microspheres for the treatment of glaucoma. For formulation optimization, dexamethasone (anti-inflammatory) and ursodeoxycholic acid (anti-apoptotic) were co-loaded by the solid-in-oil-in-water emulsion solvent extraction-evaporation technique as a first step. The incorporation of a water-soluble co-solvent (ethanol) and different amounts of dexamethasone resulted critical for the encapsulation of the neuroprotective agents and their initial release. The optimized formulation was obtained with 60\u00a0mg of dexamethasone and using an 80:20 dichloromethane:ethanol ratio. In the second step in the microencapsulation process, the incorporation of the glial cell line-derived neurotrophic factor (GDNF) was performed. The final prototype showed encapsulation efficiencies for each component above 50% with suitable properties for long-term application for at least 3\u00a0months. Physicochemical studies were performed by SEM, TEM, DSC, XRD, and gas chromatography. The evaluation of the kinetic release by the Gallagher-Corrigan analysis with Gorrasi correction helped to understand the influence of the co-microencapsulation on the delivery of the different actives from the optimized formulation. The final prototype was tested in a chronic glaucoma animal model. Rats received two intravitreal injections of the neuroprotective treatment within a 24-week follow-up study. The proposed formulation improved retinal ganglion cell (RGC) functionality examined by electroretinography. Also, it was able to maintain a neuroretinal thickness similar to that of healthy animals scanned by in vivo optical coherence tomography, and a higher RGC count on histology compared to glaucomatous animals at the end of the study.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s13346-024-01702-x","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:02:10Z","timestamp":1727953330000},"page":"1660-1684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model"],"prefix":"10.1007","volume":"15","author":[{"given":"Alba","family":"Arag\u00f3n-Navas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jesus","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Munuera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Garc\u00eda-Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Sub\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Villacampa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Garc\u00eda-Feijoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Pablo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Garcia-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Herrero-Vanrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-7872","authenticated-orcid":false,"given":"Irene","family":"Bravo-Osuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"issue":"12","key":"1702_CR1","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221\u201334.","journal-title":"Lancet Glob Health."},{"key":"1702_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390.","journal-title":"Ophthalmology"},{"issue":"3","key":"1702_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.pop.2015.05.008","volume":"42","author":"AV Mantravadi","year":"2015","unstructured":"Mantravadi AV, Vadhar N. Glaucoma. Primary Care - Clinics in Office Practice. 2015;42(3):437\u201349.","journal-title":"Primary Care - Clinics in Office Practice."},{"issue":"1","key":"1702_CR4","first-page":"73","volume":"89","author":"AC Gauthier","year":"2016","unstructured":"Gauthier AC, Liu J. Neurodegeneration and neuroprotection in glaucoma. Yale J Biol Med. 2016;89(1):73\u20139.","journal-title":"Yale J Biol Med."},{"key":"1702_CR5","doi-asserted-by":"publisher","first-page":"173208","DOI":"10.1016\/j.ejphar.2020.173208","volume":"881","author":"S Naik","year":"2020","unstructured":"Naik S, Pandey A, Lewis SA, Rao BSS, Mutalik S. Neuroprotection: a versatile approach to combat glaucoma. Eur J Pharmacol. 2020;881:173208.","journal-title":"Eur J Pharmacol"},{"key":"1702_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00441-013-1584-z","volume":"353","author":"Y Liu","year":"2013","unstructured":"Liu Y, Pang IH. Challenges in the development of glaucoma neuroprotection therapy. Cell Tissue Res. 2013;353:253\u201360.","journal-title":"Cell Tissue Res"},{"issue":"2","key":"1702_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","volume":"31","author":"M Almasieh","year":"2012","unstructured":"Almasieh M, Wilson AM, Morquette B, Vargas JLC, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31(2):152\u201381.","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"1702_CR8","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.drudis.2019.03.022","volume":"24","author":"A Arranz-Romera","year":"2019","unstructured":"Arranz-Romera A, Esteban-P\u00e9rez S, Garcia-Herranz D, Arag\u00f3n-Navas A, Bravo-Osuna I, Herrero-Vanrell R. Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases. Drug Discov Today. 2019;24(8):1644\u201353.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1702_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.exer.2010.04.002","volume":"91","author":"J Qu","year":"2010","unstructured":"Qu J, Wang D, Grosskreutz CL. Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res. 2010;91(1):48\u201353.","journal-title":"Exp Eye Res"},{"key":"1702_CR10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejphar.2016.03.064","volume":"787","author":"R Russo","year":"2016","unstructured":"Russo R, Varano GP, Adornetto A, Nucci C, Corasaniti MT, Bagetta G, Morrone LA. Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation. Eur J Pharmacol. 2016;787:134\u201342.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1702_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-vision-102016-061422","volume":"3","author":"M Almasieh","year":"2017","unstructured":"Almasieh M, Levin LA. Neuroprotection in Glaucoma: Animal Models and Clinical Trials. Annu Rev Vis Sci. 2017;3(1):91\u2013120.","journal-title":"Annu Rev Vis Sci"},{"issue":"1","key":"1702_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/jnr.24256","volume":"97","author":"X Wei","year":"2019","unstructured":"Wei X, Cho KS, Thee EF, Jager MJ, Chen DF. Neuroinflammation and microglia in glaucoma: time for a paradigm shift. J Neurosci Res. 2019;97(1):70\u20136.","journal-title":"J Neurosci Res"},{"key":"1702_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2019.01.012","volume":"297","author":"A Arranz-Romera","year":"2019","unstructured":"Arranz-Romera A, Davis BM, Bravo-Osuna I, Esteban-P\u00e9rez S, Molina-Mart\u00ednez IT, Shamsher E, Ravindran N, Guo L, Cordeiro MF, Herrero-Vanrell R. Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. J Control Release. 2019;297:26\u201338.","journal-title":"J Control Release"},{"issue":"1","key":"1702_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0169-409X(01)00200-9","volume":"52","author":"R Herrero-Vanrell","year":"2001","unstructured":"Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev. 2001;52(1):5\u201316.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"1702_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ajhp\/62.7.691","volume":"62","author":"DA Lee","year":"2005","unstructured":"Lee DA, Higginbotham EJ. Glaucoma and its treatment: A review. Am J Health Syst Pharm. 2005;62(7):691\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1702_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0169-409X(95)00018-3","volume":"16","author":"GA Peyman","year":"1995","unstructured":"Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16(1):107\u201323.","journal-title":"Adv Drug Deliv Rev"},{"key":"1702_CR17","doi-asserted-by":"crossref","unstructured":"Samoil\u0103 L, Vo\u0219tinaru O, Dinte E, Bodoki AE, Iacob BC, Bodoki E, et al. Topical treatment for retinal degenerative pathologies: a systematic review. Int J Mol Sci. 2023;24:8045. Available from\u00a0https:\/\/www.mdpi.com\/1422-0067\/24\/9\/8045\/htm.\u00a0Accessed 19 Feb 2024.","DOI":"10.3390\/ijms24098045"},{"key":"1702_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jconrel.2024.01.063","volume":"367","author":"MB Appell","year":"2024","unstructured":"Appell MB, Pejavar J, Pasupathy A, Rompicharla SVK, Abbasi S, Malmberg K, et al. Next generation therapeutics for retinal neurodegenerative diseases. J Control Release. 2024;367:708\u201336.","journal-title":"J Control Release"},{"key":"1702_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2018.11.012","volume":"293","author":"V Delplace","year":"2019","unstructured":"Delplace V, Ortin-Martinez A, Tsai ELS, Amin AN, Wallace V, Shoichet MS. Controlled release strategy designed for intravitreal protein delivery to the retina. J Control Release. 2019;293:10\u201320.","journal-title":"J Control Release"},{"key":"1702_CR20","doi-asserted-by":"crossref","unstructured":"Herrero-Vanrell R, Cardillo JA. Ocular pharmacokinetic, drug bioavailability, and intraocular drug delivery systems. Retinal Pharmacotherapy. 2010.","DOI":"10.1016\/B978-1-4377-0603-1.00014-4"},{"key":"1702_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s13346-016-0336-5","volume":"6","author":"I Bravo-Osuna","year":"2016","unstructured":"Bravo-Osuna I, Andr\u00e9s-Guerrero V, Pastoriza Abal P, Molina-Mart\u00ednez IT, Herrero-Vanrell R. Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases. Drug Deliv Transl Res. 2016;6:686\u2013707.","journal-title":"Drug Deliv Transl Res"},{"key":"1702_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.preteyeres.2014.04.002","volume":"42","author":"R Herrero-Vanrell","year":"2014","unstructured":"Herrero-Vanrell R, Bravo-Osuna I, Andr\u00e9s-Guerrero V, Vicario-de-la-Torre M, Molina-Mart\u00ednez IT. The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. Prog Retin Eye Res. 2014;42:27\u201343.","journal-title":"Prog Retin Eye Res"},{"key":"1702_CR23","doi-asserted-by":"crossref","unstructured":"de Hoz R, Rojas B, Ram\u00edrez ZA, Salazar J, Gallego B, Trivi\u00f1o A, et al. Assessment of polyesteramide of PEA Microparticles for in vivo intraocular injections. Acta Ophthalmol. 2013;91(s252).","DOI":"10.1111\/j.1755-3768.2013.F005.x"},{"issue":"7","key":"1702_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1517\/14656566.2011.571209","volume":"12","author":"NV Saraiya","year":"2011","unstructured":"Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother. 2011;12(7):1127\u201331.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1702_CR25","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/1120672120929960","volume":"31","author":"J Ruiz-Medrano","year":"2021","unstructured":"Ruiz-Medrano J, Rodr\u00edguez-Leor R, Almaz\u00e1n E, Lugo F, Casado-Lopez E, Arias L, et al. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: early versus late switch. Eur J Ophthalmol. 2021;31(3):1135\u201345.","journal-title":"Eur J Ophthalmol"},{"key":"1702_CR26","first-page":"610","volume":"25","author":"A Daruich","year":"2019","unstructured":"Daruich A, Picard E, Boatright JH, Behar-Cohen F. The bile acids urso-and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol Vis. 2019;25:610.","journal-title":"Mol Vis"},{"key":"1702_CR27","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s13311-021-01009-6","volume":"18","author":"A Daruich","year":"2021","unstructured":"Daruich A, Jaworski T, Henry H, Zola M, Youale J, Parenti L, et al. Oral ursodeoxycholic acid crosses the blood retinal barrier in patients with retinal detachment and protects against retinal degeneration in an ex vivo model. Neurotherapeutics. 2021;18:1325\u201338.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1702_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jconrel.2011.06.023","volume":"156","author":"P Checa-Casalengua","year":"2011","unstructured":"Checa-Casalengua P, Jiang C, Bravo-Osuna I, Tucker BA, Molina-Mart\u00ednez IT, Young MJ, Herrero-Vanrell R. Retinal ganglion cells survival in a glaucoma model by GDNF\/Vit e PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Release. 2011;156(1):92\u2013100.","journal-title":"J Control Release"},{"key":"1702_CR29","first-page":"733","volume":"24","author":"C Garc\u00eda-Caballero","year":"2018","unstructured":"Garc\u00eda-Caballero C, Lieppman B, Arranz-Romera A, Molina-Mart\u00ednez IT, Bravo-Osuna I, Young M, et al. Photoreceptor preservation induced by intravitreal controlled delivery of gdnf and gdnf\/melatonin in rhodopsin knockout mice. Mol Vis. 2018;24:733.","journal-title":"Mol Vis"},{"key":"1702_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ijpharm.2012.07.019","volume":"436","author":"P Checa-Casalengua","year":"2012","unstructured":"Checa-Casalengua P, Jiang C, Bravo-Osuna I, Tucker BA, Molina-Mart\u00ednez IT, Young MJ, et al. Preservation of biological activity of glial cell line-derived neurotrophic factor (GDNF) after microencapsulation and sterilization by gamma irradiation. Int J Pharm. 2012;436:545\u201354.","journal-title":"Int J Pharm"},{"key":"1702_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejps.2016.03.012","volume":"92","author":"J Rodr\u00edguez Villanueva","year":"2016","unstructured":"Rodr\u00edguez Villanueva J, Bravo-Osuna I, Herrero-Vanrell R, Molina Mart\u00ednez IT, Guzm\u00e1n Navarro M. Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration. Eur J Pharm Sci. 2016;92:287\u201397.","journal-title":"Eur J Pharm Sci."},{"key":"1702_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejps.2017.02.037","volume":"103","author":"C Garc\u00eda-Caballero","year":"2017","unstructured":"Garc\u00eda-Caballero C, Prieto-Calvo E, Checa-Casalengua P, Garc\u00eda-Mart\u00edn E, Polo-Llorens V, Garc\u00eda-Feijoo J, Molina-Mart\u00ednez IT, Bravo-Osuna I, Herrero-Vanrell R. Six month delivery of GDNF from PLGA\/vitamin E biodegradable microspheres after intravitreal injection in rabbits. Eur J Pharm Sci. 2017;103:19\u201326.","journal-title":"Eur J Pharm Sci"},{"key":"1702_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14010050","volume":"14","author":"A Arranz-Romera","year":"2021","unstructured":"Arranz-Romera A, Hernandez M, Checa-Casalengua P, Garcia-Layana A, Molina-Martinez IT, Recalde S, et al. A Safe GDNF and GDNF\/BDNF controlled delivery system improves migration in human retinal pigment epithelial cells and survival in retinal ganglion cells: potential usefulness in degenerative retinal pathologies. Pharmaceuticals (Basel). 2021;14:1\u201324.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"1702_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/pharmaceutics16030406","volume":"16","author":"J Rodr\u00edguez Villanueva","year":"2024","unstructured":"Rodr\u00edguez Villanueva J, de la Villa P, Herrero-Vanrell R, Bravo-Osuna I, Guzm\u00e1n-Navarro M. Useful role of a new generation of dexamethasone, vitamin e and human serum albumin microparticles in the prevention of excitotoxicity injury in retinal ocular diseases. Pharmaceutics. 2024;16(3):406.","journal-title":"Pharmaceutics."},{"issue":"1","key":"1702_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/exer.1996.0184","volume":"64","author":"JC Morrison","year":"1997","unstructured":"Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res. 1997;64(1):85\u201396.","journal-title":"Exp Eye Res"},{"issue":"2","key":"1702_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/pharmaceutics13020237","volume":"13","author":"D Garcia-Herranz","year":"2021","unstructured":"Garcia-Herranz D, Rodrigo MJ, Subias M, Martinez-Rincon T, Mendez-Martinez S, Bravo-Osuna I, et al. Novel use of plga microspheres to create an animal model of glaucoma with progressive neuroretinal degeneration. Pharmaceutics. 2021;13(2):237.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1702_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/biomedicines9060682","volume":"9","author":"MJ Rodrigo","year":"2021","unstructured":"Rodrigo MJ, Garcia-Herranz D, Subias M, Martinez-Rinc\u00f3n T, Mendez-Mart\u00ednez S, Bravo-Osuna I, et al. Chronic glaucoma using biodegradable microspheres to induce intraocular pressure elevation. Six-month follow-up. Biomedicines. 2021;9(6):682.","journal-title":"Biomedicines"},{"key":"1702_CR38","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1080\/10717544.2021.1998245","volume":"28","author":"MJ Rodrigo","year":"2021","unstructured":"Rodrigo MJ, Garcia-Herranz D, Arag\u00f3n-Navas A, Subias M, Martinez-Rinc\u00f3n T, Mendez-Mart\u00ednez S, et al. Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres. Drug Deliv. 2021;28:2427\u201346.","journal-title":"Drug Deliv"},{"key":"1702_CR39","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1080\/10717544.2022.2096712","volume":"29","author":"A Arag\u00f3n-Navas","year":"2022","unstructured":"Arag\u00f3n-Navas A, Rodrigo MJ, Garcia-Herranz D, Martinez T, Subias M, Mendez S, et al. Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone\/fibronectin-loaded PLGA microspheres. Drug Deliv. 2022;29:2357\u201374.","journal-title":"Drug Deliv"},{"key":"1702_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijms25010009","volume":"25","author":"I Munuera","year":"2023","unstructured":"Munuera I, Aragon-Navas A, Villacampa P, Gonzalez-Cela MA, Sub\u00edas M, Pablo LE, et al. Chronic Glaucoma Induced in Rats by a Single Injection of Fibronectin-Loaded PLGA Microspheres: IOP-Dependent and IOP-Independent Neurodegeneration. Int J Mol Sci. 2023;25:9.","journal-title":"Int J Mol Sci."},{"key":"1702_CR41","unstructured":"EMA. Guideline on the investigation of bioequivalence. 2010."},{"issue":"2","key":"1702_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0168-3659(00)00305-9","volume":"69","author":"KM Gallagher","year":"2000","unstructured":"Gallagher KM, Corrigan OI. Mechanistic aspects of the release of levamisole hydrochloride from biodegradable polymers. J Control Release. 2000;69(2):261\u201372.","journal-title":"J Control Release"},{"issue":"5","key":"1702_CR43","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/pi.5309","volume":"66","author":"G Gorrasi","year":"2017","unstructured":"Gorrasi G, Attanasio G, Izzo L, Sorrentino A. Controlled release mechanisms of sodium benzoate from a biodegradable polymer and halloysite nanotube composite. Polym Int. 2017;66(5):690\u20138.","journal-title":"Polym Int"},{"key":"1702_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123\u201333.","journal-title":"Eur J Pharm Sci."},{"key":"1702_CR45","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1023\/A:1012114825513","volume":"14","author":"E Yonemochi","year":"1997","unstructured":"Yonemochi E, Ueno Y, Ohmae T, Oguchi T, Nakajima SI, Yamamoto K. Evaluation of amorphous ursodeoxycholic acid by thermal methods. Pharm Res. 1997;14:798\u2013803.","journal-title":"Pharm Res."},{"issue":"10","key":"1702_CR46","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1021\/bm300520u","volume":"13","author":"NM Vacanti","year":"2012","unstructured":"Vacanti NM, Cheng H, Hill PS, Guerreiro JDT, Dang TT, Ma M, et al. Localized delivery of dexamethasone from electrospun fibers reduces the foreign body response. Biomacromolecules. 2012;13(10):3031\u20138.","journal-title":"Biomacromolecules"},{"key":"1702_CR47","unstructured":"European Medicines Agency. ICH guideline Q3C (R8) on impurities: guideline for residual solvents [Internet] Amsterdam. 2021 [cited 2023 Jul 04]."},{"key":"1702_CR48","unstructured":"Food and Drug Administration. International Conference on Harmonisation; Guidance on Impurities: Residual Solvents [Internet]. 1997 [cited 2023 Jul 04]."},{"key":"1702_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/ph16050646","volume":"16","author":"E Lucenteforte","year":"2023","unstructured":"Lucenteforte E, Finocchietti M, Addis A, Tettamanti M, Varano M, Parravano M, et al. Polytherapy and Multimorbidity Pattern of Users of Anti-VEGF Drugs and Dexamethasone for the Treatment of Age-Related Macular Degeneration and other Vascular Retinopathies in Clinical Practice. Pharmaceuticals. 2023;16:646.","journal-title":"Pharmaceuticals."},{"key":"1702_CR50","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/B978-0-08-087780-8.00034-6","volume-title":"Microparticles and Nanoparticles. Biomaterials Science: An Introduction to Materials in Medicine","author":"S Suri","year":"2013","unstructured":"Suri S, Ruan G, Winter J, Schmidt CE. Microparticles and Nanoparticles. Biomaterials Science: An Introduction to Materials in Medicine. Third Edition. Elsevier Inc; 2013. p. 360\u201388.","edition":"Third Edition"},{"key":"1702_CR51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijpharm.2016.01.020","volume":"499","author":"F Ramazani","year":"2016","unstructured":"Ramazani F, Chen W, Van Nostrum CF, Storm G, Kiessling F, Lammers T, et al. Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: state-of-the-art and challenges. Int J Pharm. 2016;499:358\u201367.","journal-title":"Int J Pharm"},{"key":"1702_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02980037","volume":"27","author":"Y Yeo","year":"2004","unstructured":"Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res. 2004;27:1\u201312.","journal-title":"Arch Pharm Res"},{"issue":"1\u20132","key":"1702_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijpharm.2010.05.013","volume":"394","author":"A Rawat","year":"2010","unstructured":"Rawat A, Burgess DJ. Effect of ethanol as a processing co-solvent on the PLGA microsphere characteristics. Int J Pharm. 2010;394(1\u20132):99\u2013105.","journal-title":"Int J Pharm"},{"key":"1702_CR54","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1021\/js9600538","volume":"86","author":"I Katzhendler","year":"1997","unstructured":"Katzhendler I, Hoffman A, Goldberger A, Friedman M. Modeling of drug release from erodible tablets. J Pharm Sci. 1997;86:110\u20135.","journal-title":"J Pharm Sci"},{"key":"1702_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jconrel.2017.09.029","volume":"266","author":"M Zhao","year":"2017","unstructured":"Zhao M, Rodr\u00edguez-Villagra E, Kowalczuk L, Le Normand M, Berdugo M, Levy-Boukris R, et al. Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. J Control Release. 2017;266:187\u201397.","journal-title":"J Control Release"},{"issue":"5","key":"1702_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0361-9230(00)00275-6","volume":"52","author":"PD Drew","year":"2000","unstructured":"Drew PD, Chavis JA. Inhibition of microglial cell activation by cortisol. Brain Res Bull. 2000;52(5):391\u20136.","journal-title":"Brain Res Bull"},{"issue":"4","key":"1702_CR57","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/(SICI)1097-4695(19990915)40:4<513::AID-NEU8>3.0.CO;2-D","volume":"40","author":"L Vardimon","year":"1999","unstructured":"Vardimon L, Ben-Dror I, Avisar N, Oren A, Shiftan L. Glucocorticoid control of glial gene expression. J Neurobiol. 1999;40(4):513\u201327.","journal-title":"J Neurobiol"},{"key":"1702_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","volume":"65","author":"MT Pardue","year":"2018","unstructured":"Pardue MT, Allen RS. Neuroprotective strategies for retinal disease. Prog Retin Eye Res. 2018;65:50\u201376.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1702_CR59","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1006\/nbdi.2002.0543","volume":"11","author":"G Straten","year":"2002","unstructured":"Straten G, Schmeer C, Kretz A, Gerhardt E, K\u00fcgler S, Schulz JB, et al. Potential synergistic protection of retinal ganglion cells from axotomy-induced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X-chromosome-linked inhibitor of apoptosis. Neurobiol Dis. 2002;11(1):123\u201333.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1702_CR60","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0306-4522(01)00557-7","volume":"110","author":"PD Koeberle","year":"2002","unstructured":"Koeberle PD, Ball AK. Neurturin enhances the survival of axotomized retinal ganglion cells in vivo: combined effects with glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor. Neuroscience. 2002;110(3):555\u201367.","journal-title":"Neuroscience"},{"key":"1702_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajo.2019.02.008","volume":"203","author":"CJ Siegfried","year":"2019","unstructured":"Siegfried CJ, Shui YB. Intraocular oxygen and antioxidant status: new insights on the effect of vitrectomy and glaucoma pathogenesis. Am J Ophthalmol. 2019;203:12\u201325.","journal-title":"Am J Ophthalmol"},{"key":"1702_CR62","doi-asserted-by":"crossref","unstructured":"Gramlich OW, Beck S, von Thun und Hohenstein-Blaul N, Boehm N, Ziegler A, Vetter JM, et al. Enhanced insight into the autoimmune component of glaucoma: IgG autoantibody accumulation and pro-inflammatory conditions in human glaucomatous retina. PloS one. 2013; 8(2): e57557.","DOI":"10.1371\/journal.pone.0057557"},{"issue":"13","key":"1702_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/iovs.62.13.9","volume":"62","author":"MJ Rodrigo","year":"2021","unstructured":"Rodrigo MJ, Martinez-Rincon T, Subias M, Mendez-Martinez S, Pablo LE, Polo V, et al. Influence of sex on neuroretinal degeneration: Six-month follow-up in rats with chronic glaucoma. Invest Ophthalmol Vis Sci. 2021;62(13):9\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1702_CR64","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ophtha.2015.11.031","volume":"123","author":"MPY Chan","year":"2016","unstructured":"Chan MPY, Grossi CM, Khawaja AP, Yip JLY, Khaw KT, Patel PJ, et al. Associations with intraocular pressure in a large cohort: Results from the UK Biobank. Ophthalmology. 2016;123(4):771\u201382.","journal-title":"Ophthalmology"},{"issue":"12","key":"1702_CR65","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/biomedicines9121792","volume":"9","author":"MJ Rodrigo","year":"2021","unstructured":"Rodrigo MJ, Sub\u00edas M, Montol\u00edo A, M\u00e9ndez-Mart\u00ednez S, Mart\u00ednez-Rinc\u00f3n T, Arias L, et al. Analysis of parainflammation in chronic glaucoma using vitreous-oct imaging. Biomedicines. 2021;9(12):1792.","journal-title":"Biomedicines"},{"key":"1702_CR66","doi-asserted-by":"publisher","first-page":"20622","DOI":"10.1038\/s41598-022-24954-4","volume":"12","author":"MJ Rodrigo","year":"2022","unstructured":"Rodrigo MJ, Bravo-Osuna I, Subias M, Montol\u00edo A, Cego\u00f1ino J, Martinez-Rinc\u00f3n T, et al. Tunable degrees of neurodegeneration in rats based on microsphere-induced models of chronic glaucoma. Sci Rep. 2022;12:20622.","journal-title":"Sci Rep"},{"issue":"10","key":"1702_CR67","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1167\/iovs.06-0299","volume":"47","author":"AR Rudnicka","year":"2006","unstructured":"Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: A Bayesian meta-analysis. Invest Ophthalmol Vis Sci. 2006;47(10):4254\u201361.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1702_CR68","first-page":"358","volume":"358","author":"MPY Chan","year":"2017","unstructured":"Chan MPY, Broadway DC, Khawaja AP, Yip JLY, Garway-Heath DF, Burr JM, et al. Glaucoma and intraocular pressure in EPIC-Norfolk Eye Study: cross sectional study. BMJ. 2017;358:358-j3889.","journal-title":"BMJ."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01702-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01702-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01702-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:45:39Z","timestamp":1743889539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01702-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1702"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01702-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4350813\/v1","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"16 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All work with animals was performed following the Association for the Research in Vision and Ophthalmology (ARVO) statement on the Use of Animals and was previously approved by the Ethics Committee for Animal Research (P179\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}